#1 out of 2525.88%
health21h ago
Patients, doctors hail ‘revolutionary’ new drug for pancreatic cancer
Wbez.org and 5 more
- In previously treated metastatic pancreatic cancer, daraxonrasib achieved a median overall survival of 13.2 months versus 6.7 months with standard chemotherapy.
- The daily pills nearly doubled survival time, with fewer severe side effects, in a study that randomly assigned the experimental drug or more chemotherapy to 500 patients whose metastatic, or spreading, cancer had quit responding to prior treatment.
- Revolution Medicines' drug uses what's essentially a molecular glue to bind with multiple KRAS subtypes.
Vote 17







